Drug Profile
Insulin suspension isophane/insulin biosimilar - Julphar
Alternative Names: Biosimilar human normal insulin/protaminated insulin suspension - Julphar; Human biphasic insulin - Julphar; Insulin human 30/70 - Julphar; Julphar Insulin 30/70; Jusline 30/70; Recombinant human insulin/protamine insulin mixture - JulpharLatest Information Update: 28 Mar 2019
Price :
$50
*
At a glance
- Originator Julphar Gulf Pharmaceutical Industries
- Class Antihyperglycaemics; Insulins; Pancreatic hormones
- Mechanism of Action Ornithine decarboxylase stimulants; Phosphokinase stimulants; Protein tyrosine kinase stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Diabetes mellitus
Most Recent Events
- 28 Mar 2019 No recent reports of development identified for phase-I development in Diabetes-mellitus(In volunteers) in Germany (SC, Injection)
- 09 Jun 2017 Interim efficacy and adverse events data from a phase I trial in Diabetes mellitus presented at the 77th Annual Scientific Sessions of the American Diabetes Association (ADA-2017)
- 01 Jun 2016 Julphar completes a phase I trial for Diabetes mellitus in Germany (SC) (NCT02631928)